2023 annual financial data
Entrada Therapeutics 2023 Operating margin
Direct answer
Operating margin was -2.45%.
Operating income was -3,162,000 USD and net income was -6,685,000 USD.
Operating cash flow was 139,803,000 USD.
Get free Entrada Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 129,013,000 USD
- Operating income
- -3,162,000 USD
- Net income
- -6,685,000 USD
- Operating cash flow
- 139,803,000 USD